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doi:10.1016/j.ejvs.2011.04.014Abstract Objective: Abdominal aortic aneurysm (AAA) repairs, both elective and rupture,
are associated with significant blood loss often requiring transfusion. Cell-salvage autotransfu-
sion has been developed to reduce the need for allogeneic blood. We review the literature to
delineate the role of cell salvage in reducing allogeneic blood use in open AAA repairs.
Methods: A systematic search of the English-language literature was performed using the
PubMed, Embase and Cochrane databases up to August 2010.
Results: Twenty-three studies were identified. Whilst some data are conflicting, cell salvage
appears to reduce overall use and exposure to allogeneic blood, and reduces length of inten-
sive care unit and hospital stay after elective AAA repairs. There may be additional benefit by
combining cell salvage with other blood-conservation techniques. Use of cell salvage in
ruptured AAA repairs consistently reduced blood-product requirements.
Conclusions: Cell salvage appears to reduce blood-product use in both elective and rupture
AAA repairs. Owing to the heterogeneity in methodology of published data, further study
may be required before cell salvage becomes standard practice in open AAA repairs.
ª 2011 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.Abdominal aortic aneurysm (AAA) repairs, both elective and
ruptures, are associated with a predictable blood loss,
often from opening the aneurysm sac and back bleeding
from lumbar arteries. Losses commonly range from 1 to
3 l.1,2 High intra-operative blood losses are associated with
bowel ischaemia and multi-organ failure,3 and an increased65 221278.
ox.ac.uk (A. Handa).
lsevier Ltd on behalf of Europeanmorbidity and mortality.4 The UK aloneprovides around
3500 elective and 1500 emergency AAA operations per
year5; hence, aortic surgery results in a vast cumulative
blood loss and a significant need for transfusion.
Allogeneic blood transfusion has many related problems.
There is a risk of transmission of infectious diseases, such as
AIDS and hepatitis,6 which although reduced has not been
eliminated.7 Adverse reactions are also reported, such as
anaphylaxis, transfusion-related lung injury and haemolytic
reactions.8 Allogeneic blood may be susceptible toSociety for Vascular Surgery.
Figure 1 Flowchart of studies identified.
578 S. Shantikumar et al.bacterial contamination,9 and some studies have shown
blood transfusions to be immunosuppressive10 and to
prevent the normal hypercoagulable response to
bleeding.11 Finally, the use of allogeneic transfusions has
considerable financial implications.12 Large transfusions are
associated with myocardial infarction, acute renal failure,
acute respiratory distress syndrome and death following
repair of AAA.13,14
Autologous transfusion e the transfusion of the patient’s
own blood e is already widely used in orthopaedic surgery,
and evidence suggests it has reduced the need for alloge-
neic transfusion.15 However, the evidence for autologous
blood transfusion in vascular surgery is not yet conclusive.16
The aims of this review are to: (1) give a brief historical
account of cell salvage, (2) to summarise the available
literature concerning blood-product use and the role of
cell-saver autotransfusion, with or without other autolo-
gous transfusion methods, in the repair of abdominal aortic
aneurysms, both elective and ruptures and (3) where
possible, to perform quantitative analyses regarding
complications and outcomes.
Methods
A literature search was performed using the PubMed (from
1966), Embase (from 1974) and Cochrane databases. The
last search was performed in August 2010. Results were
limited to human studies written in the English language.
The key search words used were (AAA or aneurysm) AND
(cell salvage or cell saver or autotransfusion). Eligible
studies included those which included data on the use of
cell salvage in abdominal-aortic-aneurysm repairs. Study
type was neither an inclusion nor an exclusion criterion.
Data concerning procedures for aorto-occlusive disease
were excluded. The titles and relevant abstracts were
screened by two authors (SS and SP), with any discrepancy
resolved by mutual discussion. In addition, the references
of eligible articles were screened for further relevant
studies. In total, 23 studies were identified (Fig. 1). These
included nine uncontrolled studies (six retrospective and
three prospective), 10 non-randomised trials (seven retro-
spective and three prospective) and four randomised
controlled trials (RCTs). From these, data were extracted
using a pre-prepared table on the following: authorship,
study design, intervention, number of patients, elective/
ruptured AAAs, transfusion threshold, blood-product use,
proportion of patients transfused, complications, ICU stay
and hospital stay.
Where possible, data were pooled in a meta-analysis,
using a random-effects model, given the heterogeneity of
included studies. All statistical analyses were conducted
using RevMan (v5.1, Cochrane, UK).
Salvage Autotransfusion
Salvage autotransfusion describes the collection of blood
that’s shed during surgery followed by its immediate rein-
fusion. It was first performed in 1885 by John Duncan,
surgeon at the Edinburgh Royal Infirmary, who auto-
transfused a patient requiring amputation after having his
leg crushed in a railway incident.17 Eight ounces of thepatient’s own blood, mixed with distilled water, was
successfully transfused.17
Autologous transfusion has advantages and disadvan-
tages over allogeneic transfusion. Autologous blood is
normothermic, less expensive and has a better immediate
oxygen-carrying capacity.18 In addition, autotransfusion is
accepted by some Jehovah’s witnesses.19 However, salvage
techniques require additional equipment and trained
personnel, and autologous transfusion has been associated
with coagulopathies, haemolysis, embolism and bacterial
contamination.20,21
Two different techniques of intra-operative autotrans-
fusion have been described: unwashed whole-blood auto-
transfusion (WBA) and concentrated-blood autotransfusion.
WBA was first described in 1968 by Klebanoff and Watkins22
and later used in 10 patients with major trauma in Vietnam
in 1970.23 Shed blood is filtered to remove large particu-
lates, but not washed, and immediately reinfused. Plate-
lets and plasma proteins are returned, but so are unwanted
activated coagulation factors and haemolytic degradation
products, which increase the risk of acute renal failure and
disseminated intravascular coagulation.
Concentrated-blood autotransfusion (cell salvage) was
described in 1968 by Wilson and Taswell.24 Shed blood is
mixed with anticoagulant, washed, filtered and concen-
trated before being returned to the patient. Potentially
toxic products of injured cells and procoagulants are
Cell Salvage in Abdominal Aortic Aneurysm Repairs 579reduced, but essential blood elements, such as platelets,
plasma proteins and clotting factors, are also eliminated.25
Early clinical studies reported significant coagulation
derangements following WBA.26 This led to the use of
citrate anticoagulate and limiting the amount of auto-
transfusion (e.g., to 3000 ml).27,28 With these adjustments,
some studies initially found that WBA could be used without
adverse clinical complications.29e31 More recently,
however, lethal haemostatic disturbances have been
reported with WBA.2,32 Experimental animal and human
studies comparing cell saver (CS) with WBA showed less
haemostatic disturbance and less haemolysis in the CS
group,33,34 and an RCT found that WBA was associated with
a longer ICU and hospital stay.35 As the majority of research
has focussed on the use of cell-saving devices, it is on this
form of autotransfusion that the review will concentrate.Blood Use in AAA Surgery
Three studies have retrospectively recorded blood-product
use in elective AAA surgery.36e38 An early study by Chant
et al.36 audited transfusion requirements over 3 years in 85
consecutive patients undergoing abdominal aneurysm
surgery, although it is not clear whether these were all
elective. They found that an average of 5.9 units of blood
was transfused for aneurysm repairs, although there is no
mention of whether this was intra-operatively alone or in
total.36 Improvements in graft types and surgical technique
since this publication may account for the apparent high
blood-product use. Ho et al.37 studied blood-product use in
129 elective infrarenal AAA repairs over a 10-year period,
performed by a single surgeon. Mean intra-operative blood
loss was 1000 ml and 46% of patients required intra-
operative red cells, each needing a mean transfusion of
400 ml.37 They found that a bifurcated graft, cross-clamp
time, operation time and preoperative haemoglobin (Hb)
levels were independently associated with blood loss.37
Neither of these studies reported their threshold for
transfusion.
A recent audit documented blood-product use in elec-
tive infrarenal AAA repairs in one unit over 3 years.38 They
found that only 18 of 72 patients (25%) required transfusion
and, those who did, needed an average 2.1 units.38 The
transfusion threshold was Hb < 9 g dl1. Patients who were
transfused had an increased ICU stay, but there was no
change in their overall stay. The authors conclude that,
because their blood use was so low, there is no need for
routine autotransfusion in elective infrarenal AAA repairs.38Table 1 Uncontrolled studies considering cell saver alone.
Reference Study
Design
Number of
Patients
Goodnough42 Retrospective 184 (165 suprarenal
Healey40 Prospective 63
Huber41 Retrospective 138
Kelley-Patterson39 Prospective 40
Reddy43 Retrospective 131None of the three studies reported above mentioned the
use of blood products other than red cells.
The Role of Cell Savers (CSs) in AAA Surgery
Cell saver (CS) alone e uncontrolled studies
Five uncontrolled studies have recorded blood-product use
with routine use of a CS with very different outcomes
(Table 1).39e43 Kelly-Patteson et al. prospectively studied
40 patients undergoing elective infrarenal AAA repairs by
a single surgeon with a transfusion threshold of
Hb < 8 g dl1.39 Only 14 (35%) of the 40 patients required
transfusion intra-operatively, and three (7.5%) post-
operatively, with a mean overall blood use of 0.8 units per
patient.39 A more recent study by Healy et al. prospectively
recorded blood-product administration with routine CS use
in both elective (n Z 63) and ruptured (n Z 10) AAA over
a 3-year period.40 Mean blood loss was 1300 ml in elective
surgery and 5500 ml in ruptures. CS use meant that only 35%
of elective patients required allogeneic transfusion, whilst
all ruptured AAA did. Mean perioperative transfusion
requirements were 0.3 units (elective) and 1.0 units
(rupture).40
A retrospective study by Huber et al. routinely used CS in
138 elective infrarenal AAA repairs over a 4-year period.41
They found they transfused an average of 2.8 units of red
cells per patient, although no transfusion threshold is
given. A cost analysis of this study suggested that routine CS
use was not cost-effective unless cell salvage was over
5 units and that, while the equipment should routinely be
used as a reservoir, it should only be used as a salvage
device, if significant bleeding occurs.44 Another retrospec-
tive uncontrolled study by Goodnough et al. examined
elective infrarenal (n Z 19) and suprarenal (n Z 165) AAA
repairs over a 3-year period with routine CS use.42 They
found that 89% of patients required allogeneic transfusion
despite CS use, with a mean 3.5 units of red cells transfused
per patient.42 The large transfusion requirements may in
part be explained by the large number of suprarenal AAA
repairs, which are known to be associated with a greater
blood loss, although the authors report that there was no
difference in blood-product requirements between the
infrarenal and suprarenal repairs. A subsequent cost anal-
ysis suggested that cell salvage was only beneficial in
patients who lost over a litre of blood.42
Two retrospective uncontrolled studies reported a much
higher blood-product use than the prospective studies,Transfusion
Threshold
Mean Red
Cell Transfusion
(units)
Patients
Transfused
) e 3.5 89%
e 0.3 35%
e 2.8 e
Hb < 8 g/dl 0.8 42%
Hb < 10 g/dl 1 60%
580 S. Shantikumar et al.higher even than the reports of blood-product use in AAA
repairs without cell salvage. However, these two studies
did not indicate whether their data included postoperative
transfusions, or what the intra-operative transfusion
threshold was. However, another retrospective study in 131
patients with a transfusion threshold of Hb < 10 g dl1 only
used a mean of 1.0 units per patient.43
CS in addition to other techniques e uncontrolled
studies
Two uncontrolled retrospective studies have considered the
routine use of CS in addition to predeposit in AAA repairs
(Table 2). Predeposit describes the donation and storage of
the patient’s own blood in the weeks prior to elective
surgery, to be used for subsequent transfusion. Glazier
et al. looked at routine CS and predeposit in 43 patients
undergoing infrarenal AAA repairs.45 Only a third of patients
predeposited blood. They report an average blood loss of
770 ml. Whilst 58% of patients did not require any trans-
fusion, none of the patients who predeposited blood
required allogeneic transfusion.45 Overall, mean autologous
transfusion was 1.3 units per patient.45 Pitmann et al. also
retrospectively studied elective AAA repairs with routine
use of CSs and predeposit (n Z 100).46 Only 24 units of
blood were predonated. The mean allogeneic transfusion
requirement was 1.7 units per patient. The authors felt that
allogeneic transfusion could be eliminated, if all patients
predeposited between 2 and 3 units of blood. This may not
be feasible, however, as predeposit takes up significant
preoperative time and requires the patient to have
adequate haematopoietic capacity. Further, donated blood
has a restricted shelf life and elective operations are
frequently cancelled. Furthermore, even eligible patients
do not appear to take up the option of predeposit, and
a North American multicentre study reported a predeposit
compliance of only 5% in eligible patients undergoing
elective surgery.47
Two further uncontrolled studies included the technique
of acute normovolaemic haemodilution (ANH) in AAA
repairs. In ANH, blood is withdrawn from the patient
immediately preoperatively to be retransfused later on.
Cardiac, respiratory and renal co-morbidities may limit the
routine use of ANH in aortic surgery. A recent non-
randomised study showed ANH alone had only a modest
impact on blood conservation in AAA repairs.48 Torella et al.
retrospectively looked at the combined role of CSs and ANH
in elective infrarenal aortic surgery over a 6-year period of
a single surgeon’s practice.49 Of the 78 subjects studied, 29
(37%) required transfusion, with a median allogeneicTable 2 Uncontrolled studies considering cell saver in addition
Reference Study
Design
Methods
Used
Num
Pati
Glazier45 Retrospective CS þ predeposit 43
Pittman46 Retrospective CS þ predeposit 100
Torella49 Retrospective CS þ ANH 78
Tulloh50 Prospective CS þ predeposit þ ANH 13transfusion requirement of 0 units (interquartile range
0e2 units).49 The authors suggest that use of both CS and
ANH is better than CS alone, when compared with the
literature.49 An earlier prospective study from Tulloh et al.
looked at the combination of CS with both predonation and
ANH in 13 patients undergoing elective infrarenal AAA
repairs.50 With a transfusion threshold of 9 g dl1, four
(31%) patients required allogeneic blood, with an overall
mean transfusion of 0.7 units.50 The results of these studies
suggest there may be a benefit in combining various blood-
conservation techniques.
CS versus controls in elective repairs
Eight non-randomised controlled studies in aortic-aneurysm
repairs have been published (Table 3), with most of these
suggesting a reduced transfusion volume with CS use.51e58
Four RCTs have been reported looking at the effect of CS
use in elective AAA repairs (Table 4),1,59e61 of which three
specifically studied infrarenal aneurysms.1,59e61 Spark et al.
explored 50 infrarenal AAA repairs.59 They reported that CS
use reduced the proportion of patients exposed to alloge-
neic products (96% non-CS vs. 13% CS, no p) and volume of
red-cell use (2.5 units non-CS vs. 0.5 units CS, no p). They
also found that use of CS reduced hospital stay by 3 days
(p < 0.05).59 Clagett et al. performed a multicentre trial,
also with 50 infrarenal AAA repairs.1 Interestingly, the
authors found no significant difference in volume of allo-
geneic cell use between the two groups, both intra-
operatively and throughout their hospital stay (2.5 units
CS vs. 2.4 non-CS). A similar proportion of patients in both
groups were exposed to allogeneic blood. In addition, there
was no difference in ICU stay or hospital stay.1 Wong et al.
performed a larger randomised trial comparing the
combined use of CS and ANH versus a control group in
elective infra- and suprarenal repairs.60 In 111 aneurysm
patients, they found a reduced allogeneic requirement in
the CS/ANH group (1.7 units CS/ANH vs. 3.9 units controls,
pZ 0.02). However, use of CS and ANH neither reduced the
number of patients exposed to allogeneic blood, nor did it
affect mean hospital stay.60 Mercer et al. studied 81
patients undergoing elective infrarenal repair.61 Use of CS
reduced the proportion of patients exposed to allogeneic
blood (53% CS vs. 76%, p Z 0.038) and median volume of
blood transfused (1 units CS vs. 3 units controls, pZ 0.012).
There was no difference in hospital stay.61
These four studies vary significantly in their conclusions.
Whilst Clagett et al. found that CS use did not reduce
allogeneic blood use, they used a higher intra-operative
transfusion threshold (10 g dl1) than the other studies.to other techniques.
ber of
ents
Transfusion
threshold
Mean Red
Cell Transfusion
(units)
Patients
Transfused
e 1.3 42%
e 1.7 e
8.5 g/dl Median 0 (IQR 0-2) 37%
9 g/dl 0.7 31%
Table 3 Non-randomised controlled trials.
Reference Study
Design
Methods
Used
Number of
Patients
Transfusion
Threshold
Mean Red
Cell Transfusion
(units)
Patients
Transfused
Allums51 Retrospective CS vs.
control
10 CS,
10 control
e 0.4 CS vs.
2.6 control
(no p)
30% CS vs. 90%
control (no p)
Brown52 Retrospective CS vs.
control
40 CS,
62 control
e 1.5 CS vs.
4.8 control
(p < 0.0001)
45% CS vs. 97%
control (no p)
Markovic53 Prospective CS vs.
control
30 CS,
30 control
Hb < 10 g/dl 0.5 CS vs.
2.2 control
(p Z 0.009)
40% CS vs. 97%
control (no p)
McMahon54 Prospective CS þ predeposit
vs. control
38 CS,
16 control
e 1.9 CS vs.
3.9 control
(p < 0.001)
63% CS vs. 88%
control (p < 0.001)
Serrano55 Retrospective CS vs.
control
155 CS,
37 control
Hct <30% 2.5 CS vs.
2.9 control
(p Z ns)
71% CS vs. 87%
control (p Z 0.057)
Shuhaiber56 Retrospective CS vs.
control
60 CS,
33 control
Hb < 10 g/dl 2.4 CS vs. 2.7
control (no p)
e
Tawfick57 Retrospective CS vs.
control
74 CS,
58 control
Hb < 8.5 g/dl 3 CS vs. 6
control (p < 0.001)
e
Thomas58 Retrospective CS vs.
control
50 CS,
22 control
e 3.1 CS vs. 5.4
control (no p)
90% CS vs. 100%
control (no p)
Cell Salvage in Abdominal Aortic Aneurysm Repairs 581Furthermore, salvaged cells were only reinfused if more
than 400 ml was available for processing. Spark et al. found
a significant improvement in allogeneic exposure, volume
of blood-product use and hospital stay, but this was a small
single-centre study and no comment was made regarding
blinding. Furthermore, it is not clear whether the docu-
mented transfusions were intra-operative only. If so,
including the postoperative blood requirements may affect
the final outcomes. Whilst Wong et al. documented
a reduction in allogeneic blood requirements, their study
group underwent both CS and ANH, and included suprarenal
repairs; hence, the results are not directly comparable.
A meta-analysis of the four RCTs has recently been
published.62 The authors suggested that CS use decreased
the requirement for allogeneic blood overall. However,
when the results from the largest study by Wong et al.,
where the study patients underwent both CS and ANH, are
removed from the analysis, the difference was no longer
significant. We combined all the controlled trialsTable 4 Randomised controlled trials.
Reference Methods Used Number of
Patients
Transfusi
Threshol
Clagett1 CS vs. control 25 CS,
25 control
Hb < 10
Mercer61 CS vs. control 40 CS,
41 control
Hb < 8 g
Spark59 CS vs. control 23 CS,
27 control
Hct < 25
Wong60 CS þ ANH
vs. control
59 CS,
52 control
Hb < 8 g(randomised and non-randomised) of CS versus no autolo-
gous transfusion in a meta-analysis to determine if use of
a CS (1) decreased the volume of blood-product use and (2)
decreased the proportion of patients receiving blood. Due
to the heterogeneity in trial design, a random-effects
model was used. The trials, which combined CS with
another technique, were excluded from this analysis.
Eight trials (three RCTs and five non-randomised studies)
reported the proportion of patients receiving blood
(Fig. 2).Due to a significant heterogeneity between studies
(I2 Z 89%), a random-effects model was used. We found
that cell salvage reduced the risk of requiring blood-
product administration for AAA repair (risk ratio (RR)
0.61, 95% confidence interval (CI) 0.44e0.84, p < 0.002).
The magnitude of this effect was similar when only the
three relevant RCTs were analysed (RR 0.63, 95% CI
0.37e1.07). Ten trials (three RCTs and seven non-
randomised) reported a mean red-cell transfusion for
patients undergoing AAA repair. Unfortunately, these dataon
d
Mean Red Cell
Transfusion (units)
Patients Transfused
g/dl 2.4 CS vs. 2.5
control (p Z ns)
66% CS vs. 72%
control (p Z ns)
/dl 1 CS vs. 3
control (p Z 0.012)
53% CS vs. 76%
control (p Z 0.038)
% 0.5 CS vs.
2.5 control (no p)
13% CS vs. 96%
control (no p)
/dl 1.7 CS vs.
3.9 control (p Z 0.02)
e
Figure 2 Meta-analysis of the number of patients requiring allogeneic transfusion in the cell saver and control groups. The
diamond on the left of the line of no difference suggests a benefit of cell salvage.
582 S. Shantikumar et al.could not be analysed statistically, as not all the required
figures were published. However, we calculated that, in the
852 patients studied, a combined average of 2.2 units of red
cells were given to each patient in the CS group, compared
with 3.7 units per patient in the controls (a reduction of 1.5
units per person). A recent study looked at complications
and outcomes following cell salvage in abdominal aortic
surgery.63 The authors concluded that, at worst, cell
salvage does not change the complication rate after elec-
tive aortic surgery, and may even reduce it.63 However,
a statistical analysis of such data is not possible due to the
variations in reporting.
Role of CSs in ruptured aneurysm repairs
Five non-randomised controlled studies reported on the role
of CSs in ruptured aneurysm repairs (Table 5).53,56,57,64,65
Posacioglu et al. retrospectively looked at blood loss in
suprarenal and infrarenal ruptured AAA repairs by a single
surgeon.64 Of 56 subjects, 40 repairs used the CS and 16 did
not. The CS group required fewer allogeneic red cells (mean
5.8 units non-CS vs. 3.6 units CS, pZ 0.026) and fewer units
of fresh-frozen plasma (FFP) (mean 4.5 units non-CS vs. 1.5
units CS, p Z 0.006).64 The authors also reported a shorter
hospital stay in the CS group but no significant difference in
mortality.64 Tawfick et al. studied retrospectively ruptured
AAA repairs over a 9-year period.57 Of 55 patients, 27 had CS
and 28 did not. Mean blood transfusions were significantly
lower in theCS patients (CS 6 units vs.non-CS 12 units). There
was no significant difference in platelet and FFP transfusion
between the CS and non-CS groups, although use of CS
reduced ICU and hospital stay.57 There was no mention as to
the location of the aneurysms. The third retrospectiveTable 5 Cell saver use in ruptured aneurysms (all non-randomi
Reference Study Design Number of Patients
Markovic53 Prospective 30 CS, 30 control
Posacioglu64 Retrospective 40 CS, 16 control
Serracino-Inglott65 Prospective 40 CS, 116 control
Shuhaiber56 Retrospective 4 CS, 21 control
Tawfick57 Retrospective 27 CS, 28 controlreport, from Shuhaiber et al., found no significant reduction
in transfusion volumes in ruptured aneurysms, although this
study only included 25 patients.56
A prospective study reported by Serracino-Inglott et al.
examined 154 ruptured AAA repairs over a 4-year period.65
Of these, 114 operations did not use CSs and 40 did. The
mean allogeneic-blood-transfusion requirement was 4 units
in the CS group and 7 units in the non-CS group
(p < 0.001).65 While there was no difference in the rate of
postoperative complications between the two groups, the
authors report an increased survival in the CS group (76% vs.
56%), although this analysis excluded patients who died in
theatre.65 A second prospective study reported by Markovic
et al. of 60 patients also suggested a significant reduction in
transfusion volume, with a transfusion threshold of
Hb < 10 g dl1.53
Although none of the above three studies were rando-
mised, likely due to the unpredictability of rupture admis-
sions and difficulties with ethical approval, there appears
to be a consistent significant reduction in allogeneic
transfusion when CSs are used in the repair of ruptured
aneurysms. Although a pooled analysis was again not
statistically possible, we calculated that the average red-
cell requirement per patient having a ruptured AAA repair
was 3.6 units in the CS group versus 7.0 units in the control
group.
Discussion
Although many descriptive studies have looked at the role
of cell salvage in AAA repairs, little randomised controlled
data are available, and those that exist describe conflicting
results regarding allogeneic blood use. These discrepanciessed).
Transfusion Threshold Mean Red Cell Transfusion
(units)
Hb < 10 g/dl 0.5 CS vs. 2.2 control
(p Z 0.009)
Hct < 28% 3.6 CS vs. 5.8 control
(p Z 0.026)
e 4 CS vs. 7 control (p < 0.001)
Hb < 10 g/dl 8 CS vs. 9 control (no p)
Hb < 8.5 g/dl 6 CS vs. 12 control (p < 0.001)
Cell Salvage in Abdominal Aortic Aneurysm Repairs 583are explained by the heterogeneity in methodology.
Important variables include the type of aneurysm (infrare-
nal/suprarenal/complex), the use of different transfusion
devices and varying practices in heparin administration and
reversal. Furthermore, different transfusion thresholds
have been described.
The aim of cell salvage is to reduce overall blood-
product use and to reduce the proportion of patients
exposed to allogeneic blood. We therefore performed
a meta-analysis of all controlled trials (randomised and
non-randomised). We found that CS use significantly
reduced the proportion of patients requiring transfusion for
elective AAA repair. CS use also halved the mean require-
ment for blood in both elective and ruptured AAA repairs.
An additional cost benefit would be advantageous, although
a recent analysis of an RCT found no significant savings from
cell salvage.66 Encouragingly, cell salvage does not appear
to be associated with an increase in complications and it
may have a positive effect on length of ICU and hospital
stays (Tavare, 2011 #126).
The current evidence available from controlled studies
on the effect of cell salvage in aortic aneurysm repairs
suggests a likely reduction in transfusion requirements in
both elective and emergency operations. Whilst this
suggests a role for routine cell salvage in aneurysm repairs,
local protocols need to be based on the availability of cell
salvage, the cost of blood products, the threshold for
transfusion and themean blood loss within the vascular unit.Conflict of Interest/Funding
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